drugset / Trial / NCT02835976

A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)

NCT02835976

Phase 1 Completed 6 enrolled Hoffmann-La Roche Trophos · collab
NaSingle-groupOpen-labelTreatment

Summary

This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum of carbon-14 (14C)-labeled TRO19622 and its 14C-metabolites, and to investigate the pharmacokinetics and metabolic profile of TRO19622 (olesoxime) in healthy participants.

Timeline

Start
2014-07
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Olesoxime Small molecule 600 mg Oral

Indications

No indication recorded.